Lyell Immunopharma Inc (LYEL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$14.37+0.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LYEL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 357.3% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -48.3% |
Growth built into the price is above our model estimate.
The price assumes 405.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
LYEL — earnings miss
Dated 2026-03-12
Results of Operations and Financial Condition. On March 12, 2026, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exch…
Why it matters: Maintaining sufficient cash is crucial for funding ongoing trials. A drop below expectations could raise concerns.
Worry ifCash balance is over $200 million, showing strong financial health.
Less concerning ifCash balance falls below $200 million, raising concerns about funding for clinical trials.
Why it matters: Safety data will show if new protocols reduce side effects. This affects trial success.
Supportive ifSafety data shows less Grade ≥2 diarrhea or colitis in patients with new protocols.
Worry ifSafety data shows no change or more side effects compared to earlier results.
Why it matters: This data shows how well ronde-cel works for treating LBCL. Good results could help future approvals.
Supportive ifNew data from the PiNACLE trial shows better response rates than current therapies.
Worry ifData from the PiNACLE trial shows no big change in response rates.
Why it matters: This update will show how well LYL273 works for metastatic colorectal cancer.
Supportive ifA positive safety update from the LYL273 trial in the first half of 2026.
Worry ifA negative safety update or delay in reporting data from the LYL273 trial.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$293 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $810 loss on $10,000 · 8.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,992 loss on $10,000 · 69.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This trial compares ronde-cel to standard therapies. Results will show how it competes in the market.
Watch forA progress update shows ronde-cel works better than standard therapies. It leads to longer event-free survival.
Also watch forThe update shows no major difference in event-free survival. This is compared to standard therapies.
Why it matters: The recent earnings beat shows a chance for good performance. Future updates will explain this.
Watch forLater earnings reports show ongoing growth or profit.
Also watch forFuture earnings reports show a decline or miss expectations.
Why it matters: Using less cash is important for running the business. It shows how well management controls costs.
Supportive ifNet cash use reported below $50 million for Q2 2026.
Worry ifNet cash use reported above $70 million for Q2 2026.
Why it matters: If health care revenue growth speeds up, it could help Lyell's performance.
Supportive ifHealth care revenue growth returns to near 10% or higher.
Worry ifHealth care revenue growth continues to slow below current levels.
Why it matters: Keeping track of cash is key for funding trials and operations. A drop could mean financial trouble.
Worry ifCash and equivalents are steady or increasing. This shows there is enough money for operations.
Less concerning ifCash and equivalents drop a lot, raising worries about funding for clinical trials.
Why it matters: Having enough cash is key for running operations and clinical trials.
Worry ifConfirmation that cash resources are sufficient to meet needs into Q3 2027.
Less concerning ifManagement says they need more money before Q3 2027.